

INCENTIVES FOR RESEARCH, DEVELOPMENT, AND INNOVATION IN PHARMACEUTICALS

SERIES ECONOMÍA DE LA SALUD Y GESTIÓN SANITARIA

Edited by **Vicente Ortún**

Title on the series


- 84-070-0192-9 **P. Ibern** (1999)
Incentivos y contratos en los servicios de salud
- 84-070-0233-X **M. Buglioli y V. Ortún** (2001)
Decisión clínica. Cómo entenderla y mejorarla
- 84-070-0235-6 **J. Puig-Junoy, J.L. Pinto y E. Dalmau** (2001)
El valor monetario de la salud
- 84-070-0236-4 **G. López-Casasnovas, A. García y L. Pellisé** (2001)
El control del gasto sanitario. Participación de profesionales y usuarios
- 84-070-0234-8 **J.L. Pinto, G. López-Casasnovas y V. Ortún** (2001)
Economic evaluation. From theory to practice
- 84-070-0247-X **G. López Casasnovas y B. Jönsson** (2001)
Reference pricing and pharmaceutical policy. Perspectives on economics and innovation
- 84-458-1196-7 **J. Puig-Junoy** (2002)
Análisis económico de la financiación pública de medicamentos
- 84-458-1217-3 **R. Meneu** (2002)
Variabilidad de las decisiones médicas y su repercusión sobre las poblaciones
- 84-458-1286-6 **G. López-Casasnovas** (2002)
El interfaz público-privado en sanidad
- 84-458-1308-0 **V. Ortún Rubio** (2003)
Gestión clínica y sanitaria. De la práctica diaria a la academia, ida y vuelta
- 84-458-1362-5 **J.L. Pinto, M.X. Vázquez, A. Lázaro y J.E. Martínez** (2003)
Análisis coste-beneficio en la salud. Métodos de valoración y aplicaciones
- 84-458-1430-3 **R. Meneu y S. Peiró** (2004)
Elementos para la gestión de la prescripción y la prestación farmacéutica
- 84-458-1432-X **J. Puig-Junoy, G. López-Casasnovas y V. Ortún** (2004)
¿Más recursos para la salud?
- 84-458-1447-8 **J.L. Pinto, J.M. Abellán y F.I. Sánchez** (2004)
Incorporación de las preferencias de los pacientes en las decisiones clínicas
- 84-458-1525-3 **B. González López-Valcárcel** (2005)
Difusión de las nuevas tecnologías sanitarias y políticas públicas
- 84-458-1530-X **R. Meneu, V. Ortún Rubio y F. Rodríguez Artalejo** (2005)
Innovación en gestión clínica y sanitaria
- 84-458-1578-4 **P. Ibern Regàs** (2005)
Integración asistencial. Fundamentos, experiencias y vías de avance
- 84-458-1721-3 **D. Casado Marín** (2006)
Efectos y abordajes de la dependencia: un análisis económico
- 84-458-1731-0 **A. Hidalgo Vega, J. del Llano Señarís, S. Pérez Camarero** (2006)
Recursos humanos para la salud: suficiencia, adecuación y mejora
- 978-84-458-1800-8 **I. Caballé Martín** (2007)
Gestión del laboratorio clínico
- 978-84-458-1896-1 **M. Rodríguez y R. Urbanos** (finales 2007)
Salud y desigualdad: factores determinantes y elementos para la acción
- 978-84-458-1949-4 **R. Bengoa y R. Nuño Solinís** (2008)
Curar y cuidar. Innovación en la gestión de enfermedades crónicas: una guía práctica para avanzar
- 978-84-937496-1-3 **V. Ortún** (2009)
El buen gobierno sanitario
- 978-84-4582103-9 **J. Prades y J.M. Borrás** (2011)
La organización de la atención multidisciplinar en cáncer
- 978-84-9380620-0 **V. Ortún** (2011)
La refundación de la atención primaria
- 978-84-9380621-7 **W. García-Fontes** (2011)
Incentives for Research, Development, and Innovation in Pharmaceuticals

INCENTIVES FOR RESEARCH, DEVELOPMENT, AND INNOVATION IN PHARMACEUTICALS

WALTER GARCÍA-FONTES (DIR.)
Departamento de Economía y Empresa
Universidad Pompeu Fabra, Barcelona



Series *Economía de la salud y gestión sanitaria*
Edited by *Vicente Ortún, CRES-UPF*



Springer Healthcare Ibérica SL.
Calle Arte 27- 2º A - 28033
Madrid | Spain
www.springerhealthcare.com

© 2011 Springer Healthcare Ibérica SL.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means electronic, mechanical, photocopying, recording or otherwise without the prior written permission of the copyright holder.

Although every effort has been made to ensure that drug doses and other information are presented accurately in this publication, the ultimate responsibility rests with the prescribing physician. Neither the publisher nor the authors can be held responsible for errors or for any consequences arising from the use of the information contained herein. Any product mentioned in this publication should be used in accordance with the prescribing information prepared by the manufacturers. No claims or endorsements are made for any drug or compound at present under clinical investigation.

ISBN 978-84-938062-1-7
DOI 10.1007/978-84-938062-7-9
Depósito Legal: M-47.442-2011

ISBN 978-84-938062-7-9 (eBook)

Table of contents

CHAPTER 1	
Introduction	1
<i>Walter García-Fontes</i>	
CHAPTER 2	
Incentives for innovation: a survey	5
<i>Walter García-Fontes</i>	
Introduction	5
Incentives to innovate	6
Patents and the incentives to innovate	9
The open source software model of innovation	12
Concluding remarks	13
CHAPTER 3	
Incentives for innovation: neglected diseases	15
<i>Mary Moran</i>	
Introduction	15
Types of markets	16
Markets for different firms	17
Incentives to stimulate pharma innovation	20
Review of current incentives	25
A new framework: matching incentives to products and developers	32
CHAPTER 4	
When patents are not enough: supplementary incentives for pharmaceutical innovation	39
<i>Aidan Hollis</i>	
Introduction	39
The reasons for low appropriability	40
Solutions	42
Summary	46

CHAPTER 5	
The Contribution of the United States, Europe and Japan in Discovering New Drugs: 1982 2003	49
<i>Henry Grabowski</i>	
Introduction	49
Drug quality measures in the prior literature	50
Drug quality measures and the current analysis	53
NCE inventor region versus firm headquarters region	56
R&D Productivity by región	60
Conclusions and policy considerations	64
CHAPTER 6	
The use of pay for performance for drugs: can it improve incentives for innovation?	69
<i>Adrian Towse, Louis Garrison and Ruth Puig Peiró</i>	
Introduction	69
What do we mean by pay-for-performance?	70
A framework for understanding and interpreting pay-for-performance schemes	71
Numbers and types of schemes	74
Benefits and weaknesses of pay-for-performance schemes	76
CHAPTER 7	
Drug Price Regulation: Recent Trends and Downstream Neglected Issues	81
<i>Joan Ramon Borrell</i>	
Introduction	81
Countervailing forces in drug pricing	82
Well-known results	85
Concluding remarks	92

Authors

JOAN-RAMÓN BORRELL

Joan-Ramon Borrell is Associate Professor in Economics at the University of Barcelona, Spain. He is member of the Governments and Markets Research Group. He is Research Fellow at the Public-Private Sector Research Center at IESE Business School (University of Navarra), and at the Health Economics Research Center (CRES) at the University Pompeu Fabra. His main research is at the cross-roads of industrial and public economics. He models empirically the strategic interaction of firms in markets, such as the market for pharmaceuticals or for energy. Using the estimates of models, he identifies and quantifies the impact of public policies on firm conduct, as well as the adequacy of such policies to achieve government targets, and also the overall effect of public policies on welfare.

WALTER GARCÍA-FONTES

Walter Garcia-Fontes is an associate professor at the Department of Economics and Business of Universitat Pompeu Fabra. His research interests are in Industrial Organization, firm innovation, technological change and applied econometrics. He has published his work in leading international field journals. He has coordinated various projects in the European Commission Framework Programmes studying the European chemical industry and the organizational changes related to new industrial relations.

LOUIS GARRISON

Lou Garrison is Professor and Associate Director in the Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, at the University of Washington in Seattle. His recent research focuses on designing and conducting economic and outcomes research evaluations of pharmaceutical, biotechnology, and diagnostic products, and on policy issues related to pricing and reimbursement, regulatory risk-benefit analysis, and pharmacogenetics.

HENRY GRABOWSKI

Henry G. Grabowski has been at Duke University since 1972 where he is Professor Emeritus of Economics and Director of the Program in Pharmaceuticals and Health Economics. He received his Ph.D. in economics from Princeton University in 1967. He has held visiting appointments at the Health Care Financing Administration in Washington, D.C., and the International Institute of Management in Berlin, Germany. Professor Grabowski has published numerous studies on the pharmaceutical industry, with his principal research involving the economics of the innovation process, government regulation, and market competition. He has been an advisor to the National Academy of Sciences, the Institute of Medicine, the Federal Trade Commission, and the Congressional Budget Office. He has testified before Congress several times on policy issues involving pharmaceuticals and the health care sector.

AIDAN HOLLIS

Aidan Hollis is Professor in Economics at the University of Calgary, and Vice-President of Incentives for Global Health, a US-based NGO focused on the development of the Health Impact Fund proposal. Hollis studied at Cambridge University and the University of Toronto, where he obtained a PhD in economics. His research focuses on innovation and competition in pharmaceutical markets, though he has published over thirty peer reviewed articles and two books in a range of fields of economics. In 2003-4 he served as the T.D. MacDonald Chair in Industrial Economics at the Competition Bureau. He has provided expert reports and testimony in a variety of pharmaceutical-related cases in Federal, Appeals and Supreme Court cases in Canada, and has advised companies and governments.

For more information, see the websites: <http://econ.ucalgary.ca/hollis.htm> and <http://healthimpactfund.org>

MARY MORAN

Dr Moran is Director of Policy Cures, an independent research group based in Sydney and London. She has over 20 years experience in health policy and practice, including 10 years specialising in policy related to neglected disease R&D. Mary is an Honorary Senior Lecturer at the London School of Hygiene and Tropical Medicine, and an Expert Adviser to the World Health Organisation, European Commission, European and Developing Countries Clinical Trials Partnership, Global Alliance for Vaccines and Immunisation (GAVI),

OECD and the Wellcome Trust. She was previously a doctor, diplomat, and policy analyst with Medecins Sans Frontieres.

RUHT PUIG-PEIRÓ

Ruth's current research focus is on economic appraisal methods across UK government departments, relative effectiveness and health technology assessment across European countries, and the economics of the pharmaceutical industry. Before joining the OHE in 2010, Ruth held positions as a Research Officer at the Personal Social Services Research Unit (PSSRU) at the London School of Economics and Political Science and a Researcher at the Centre for Research in Economics and Health (CRES) at Universitat Pompeu Fabra in Barcelona, Spain.

ADRIAN TOWSE

Adrian Towse is Visiting Professor at the University of York and a Visiting Senior Researcher at the Department of Public Health and Primary Care at the University of Oxford. For ten years, he served as the Non-Executive Director of the Oxford Radcliffe Hospitals NHS Trust, one of the UK's largest hospitals. Adrian joined the OHE in 1993. Adrian Towse has been Director of the Office of Health Economics since 1992.

His interests include the use of "risk-sharing" arrangements between health care payers and pharmaceutical companies to manage the introduction of new health technologies; the economics of pharmacogenetics for health care payers and for the pharmaceutical industry; economic issues around the use of public private partnerships for the development of treatments for less developed country diseases; and the economics of medical negligence - incentive properties and costs of 'no fault' versus reformed tort procedures.